Molnupiravir also known as MK-4482/ EIDD-2801 is a new investigational oral antiviral medicine that has completed its phase II clinical trials and showed promising results.

Molnupiravir is developed by Ridgeback Biotherapeutics LP in collaboration with Merck & Co. It is a potent ribonucleoside analogue that inhibits the replication of SARS-CoV-2 that is the causative agent of COVID-19. Molnupiravir has shown its activity during several preclinical models of SARS-CoV-2. It is shown that it is effective for prophylaxis, treatment, and prevention of transmission of SARS-CoV-2. The pre-clinical and clinical data of molnupiravir have also shown that it is effective against the different variants of SARS-CoV-2.
Molnupiravir, previously known as EIDD-2801, was initially developed by Drug Innovations at Emory (DRIVE) that is a non-profit biotechnology company completely owned by Emory University. They introduced it as a broad-spectrum antiviral for the treatment of equine encephalitis and influenza, but later on, laboratory tests showed that it is effective against coronaviruses as well. Now Merck is conducting its phase III clinical trials for COVID-19.
Since the pandemic had hit several antiviral drugs have been approved and are in queue to be approved, amo